

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

NCT06836232

Status	RECRUITING
Phase	Phase 2
Sponsor	Zomagen Biosciences Ltd.
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (7)

- Participants are male or female e 18 years up to d 75 years of age.
- Capable of giving signed informed consent and able to comply with the protocol
- Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
- Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
- CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP d 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)

... and 2 more (see full listing online)

Exclusion (3)

- Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
- History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
- Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.

Locations (16 total)

Local Site #840012, Tucson, Arizona, United States
Local Site #840014, Orange, California, United States
Local Site #840016, Saint Augustine, Florida, United States

... and 13 more locations